Search

Your search keyword '"Newell-Price, John"' showing total 640 results
Start Over Author "Newell-Price, John"
640 results on '"Newell-Price, John"'

252. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

Author

Wolin, Edward M., Jarzab, Barbara, Eriksson, Barbro, Walter, Thomas, Toumpanakis, Christos, Morse, Michael A., Tomassetti, Paola, Weber, Matthias M., Fogelman, David R., Ramage, John, Poon, Donald, Gadbaw, Brian, Li, Jiang, Pasieka, Janice L., Mahamat, Abakar, Swahn, Fredrik, Newell-Price, John, Mansoor, Wasat, Öberg, Kjell, Wolin, Edward M., Jarzab, Barbara, Eriksson, Barbro, Walter, Thomas, Toumpanakis, Christos, Morse, Michael A., Tomassetti, Paola, Weber, Matthias M., Fogelman, David R., Ramage, John, Poon, Donald, Gadbaw, Brian, Li, Jiang, Pasieka, Janice L., Mahamat, Abakar, Swahn, Fredrik, Newell-Price, John, Mansoor, Wasat, and Öberg, Kjell

Abstract

In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release (pasireotide LAR) with octreotide long-acting repeatable (octreotide LAR) in managing carcinoid symptoms refractory to first-generation somatostatin analogues. Adults with carcinoid tumors of the digestive tract were randomly assigned (1:1) to receive pasireotide LAR (60 mg) or octreotide LAR (40 mg) every 28 days. Primary outcome was symptom control based on frequency of bowel movements and flushing episodes. Objective tumor response was a secondary outcome. Progression-free survival (PFS) was calculated in a post hoc analysis. Adverse events were recorded. At the time of a planned interim analysis, the data monitoring committee recommended halting the study because of a low predictive probability of showing superiority of pasireotide over octreotide for symptom control (n=43 pasireotide LAR, 20.9%; n=45 octreotide LAR, 26.7%; odds ratio, 0.73; 95% confidence interval [CI], 0.27-1.97; P=0.53). Tumor control rate at month 6 was 62.7% with pasireotide and 46.2% with octreotide (odds ratio, 1.96; 95% CI, 0.89-4.32; P=0.09). Median (95% CI) PFS was 11.8 months (11.0 - not reached) with pasireotide versus 6.8 months (5.6 - not reached) with octreotide (hazard ratio, 0.46; 95% CI, 0.20-0.98; P=0.045). The most frequent drug-related adverse events (pasireotide vs octreotide) included hyperglycemia (28.3% vs 5.3%), fatigue (11.3% vs 3.5%), and nausea (9.4% vs 0%). We conclude that, among patients with carcinoid symptoms refractory to available somatostatin analogues, similar proportions of patients receiving pasireotide LAR or octreotide LAR achieved symptom control at month 6. Pasireotide LAR showed a trend toward higher tumor control rate at month 6, although it was statistically not significant, and was associated with a longer PFS than octreotide LAR.

Published
2015
Full Text
View/download PDF

254. Antisense oligomer therapy directed at the GH receptor is associated with reduction in circulating GHBP levels

Author

Trainer, Peter, primary, Newell-Price, John, additional, Ayuk, John, additional, Aylwin, Simon, additional, Rees, Aled, additional, Drake, Will, additional, Chanson, Philippe, additional, Brue, Thierry, additional, Webb, Susan, additional, Fajardo, Carmen, additional, Aller, Javier, additional, McCormack, Ann, additional, Torpy, David, additional, Atley, Lynne, additional, and Tachas, George, additional

Published
2015
Full Text
View/download PDF

255. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

Author

Wolin, Edward, primary, Jarzab, Barbara, additional, Eriksson, Barbro, additional, Walter, Thomas, additional, Toumpanakis, Christos, additional, Morse, Michael A., additional, Tomassetti, Paola, additional, Weber, Matthias M., additional, Fogelman, David, additional, Ramage, John, additional, Poon, Donald, additional, Gadbaw, Brian, additional, Li, Jiang, additional, Pasieka, Janice L., additional, Mahamat, Abakar, additional, Swahn, Fredrik, additional, Newell-Price, John, additional, Mansoor, Wasat, additional, and Öberg, Kjell, additional

Published
2015
Full Text
View/download PDF

259. A phase 2 study of antisense oligonucleotide therapy directed at the GH receptor demonstrates lowering of serum IGF1 in patients with acromegaly.

Author

Trainer, Peter, primary, Newell-Price, John, additional, Ayuk, John, additional, Aylwin, Simon, additional, Rees, Aled, additional, Drake, Will, additional, Chanson, Philippe, additional, Brue, Thierry, additional, Webb, Susan, additional, Fajardo, Carmen, additional, Aller, Javier, additional, McCormack, Ann, additional, Torpy, David, additional, Tachas, George, additional, Atley, Lynne, additional, and Bidlingmaier, Martin, additional

Published
2015
Full Text
View/download PDF

260. A Multicenter, Randomized, Blinded, Phase 3 Study of Pasireotide LAR vs Octreotide LAR in Patients with Metastatic Neuroendocrine Tumors (NET) with Disease-Related Symptoms Inadequately Controlled by Somatostatin Analogs

Author

Wolin, Edward M., Jarzab, Barbara, Eriksson, Barbro, Walter, Thomas, Toumpanakis, Christos, Morse, Michael, Tomassetti, Paola, Weber, Matthias, Fogelman, David, Ramage, John, Poon, Donald, Huang, Jerry, Hudson, Michelle, Li, Jiang, Pasieka, Janice L., Mahamat, Abakar, Swahn, Fredrik, Newell-Price, John, Mansoor, Was, Öberg, Kjell, Wolin, Edward M., Jarzab, Barbara, Eriksson, Barbro, Walter, Thomas, Toumpanakis, Christos, Morse, Michael, Tomassetti, Paola, Weber, Matthias, Fogelman, David, Ramage, John, Poon, Donald, Huang, Jerry, Hudson, Michelle, Li, Jiang, Pasieka, Janice L., Mahamat, Abakar, Swahn, Fredrik, Newell-Price, John, Mansoor, Was, and Öberg, Kjell

Published
2014

265. Colaboradores

Author

Achermann, John C., Aiello, Lloyd P., Alexander, Erik K., Allen, Rebecca H., Altshuler, David, Anderson, Mark S., Atkinson, Mark A., Bahn, Rebecca S., Barker, Jennifer M., Basson, Rosemary, Berga, Sarah L., Bhasin, Shalender, Birnbaum, Morris J., Black, Dennis M., Bose, Anirban, Boulton, Andrew J.M., Braunstein, Glenn D., Bremner, William J., Brent, Gregory A., Bringhurst, F. Richard, Brownlee, Michael, Bulun, Serdar E., Burant, Charles F., Bushinsky, David A., Cone, Roger D., Cooke, David W., Cooper, Mark E., Cryer, Philip E., Dattani, Mehul T., Davies, Terry F., de Paula, Francisco J.A., Demay, Marie B., DiVall, Sara A., Elmquist, Joel K., Filetti, Sebastiano, Gevers, Evelien F., Ghigo, Ezio, Goldberg, Anne C., Goldberg, Ira J., Gottlieb, Peter A., Grinspoon, Steven K., Grumbach, Melvin M., Hay, Ian D., Hayes, Frances J., Hickey, Martha, Hirschhorn, Joel N., Ho, Ken K.Y., Hughes, Ieuan A., Kaiser, Ursula, Kaunitz, Andrew M., Klein, Samuel, Kleinberg, David, Kronenberg, Henry M., Lamberts, Steven W.J., Lanfranco, Fabio, Larsen, P. Reed, Laurberg, Peter, Lazar, Mitchell A., Loriaux, Lynn, Low, Malcolm J., Majithia, Amit R., Marx, Stephen J., Matsumoto, Alvin M., Melmed, Shlomo, Monk, Rebeca D., Murray, Robert D., Newell-Price, John D.C., Nitsche, Joshua F., Öberg, Kjell, Plutzky, Jorge, Polonsky, Kenneth S., Radovick, Sally, Robinson, Alan G., Romijn, Johannes A., Rosen, Clifford J., Salvatore, Domenico, Schlumberger, Martin-Jean, Semenkovich, Clay F., Sluss, Patrick M., Stewart, Paul M., Strasburger, Christian J., Styne, Dennis M., van den Beld, Annewieke W., Vella, Adrian, Verbalis, Joseph G., Vinik, Aaron I., Weetman, Anthony P., Wells, Samuel A., Jr., and Young, William F., Jr.

Published
2017
Full Text
View/download PDF

268. Effectiveness of metyrapone in 195 patients with Cushing's syndrome

Author

Daniel, Eleni, primary, Aylwin, Simon, additional, Mustafa, Omar, additional, Ball, Steve, additional, Munir, Atif, additional, Boelaert, Kristien, additional, Chortis, Vasileios, additional, Cuthbertson, Daniel J, additional, Daousi, Christina, additional, Rajeev, Surya, additional, Davis, Julian, additional, Cheer, Kelly, additional, Drake, William, additional, Gunganah, Kirun, additional, Grossman, Ashley, additional, Gurnell, Mark, additional, Powlson, Andrew, additional, Karavitaki, Niki, additional, Huquet, Isabel, additional, Kearney, Tara, additional, Mohit, Kumar, additional, Meeran, Karim, additional, Hill, Neil, additional, Rees, Aled, additional, Trainer, Peter J, additional, Lansdown, Andrew J, additional, Minder, Anna-Elisabeth H, additional, and Newell-Price, John, additional

Published
2014
Full Text
View/download PDF

272. Contributors to Davidson's Principles and Practice of Medicine, 22nd Edition

Author

Abdul Razak, Albiruni Ryan, Angus, Brian J., Anstee, Quentin M., Bradbury, Andrew W., Burnett, Leslie, Byers, Mark, Craig, Jenny I.O., Cumming, Allan D., Dark, Graham, Davenport, Richard J., Dawe, Robert S., Dockrell, David, Field, Michael J., FitzPatrick, David R., Goddard, Jane, Grubb, Neil R., Hanlon, Phil, Hobson, Richard P., Ibbotson, Sally H., Innes, J. Alastair, Jones, David E., Langhorne, Peter, Lawrie, Stephen M., Leach, John Paul, Lees, Charlie W., Maartens, Gary, Macdonald, Helen M., Manson, Lynn M., Marshall, Sara E., Maxwell, Simon, McCrimmon, Rory J., McInnes, Iain B., Newby, David E., Newell-Price, John D., Nimmo, Graham R., Noble, Simon I.R., Oxenham, David R., Pearson, Ewan R., Penman, Ian D., Ralston, Stuart H., Reid, Peter T., Scott, Gordon R., Seckl, Jonathan R., Sharpe, Michael, Stewart, Peter, Strachan, Mark W.J., Sullivan, David, Sundar, Shyam, Thomas, Simon H.L., Turner, A. Neil, Walker, Simon W., Walsh, Tim, Watson, Henry, White, Julian, Wilding, John P.H., and Witham, Miles D.

Published
2016
Full Text
View/download PDF

276. A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs.

Author

Wolin, Edward M., primary, Jarzab, Barbara, additional, Eriksson, Barbro, additional, Walter, Thomas, additional, Toumpanakis, Christos, additional, Morse, Michael, additional, Tomassetti, Paola, additional, Weber, Matthias, additional, Fogelman, David R., additional, Ramage, John, additional, Poon, Donald, additional, Huang, Jerry M., additional, Hudson, Michelle, additional, Zhi, Xin, additional, Pasieka, Janice L., additional, Mahamat, Abakar, additional, Swahn, Fredrik, additional, Newell-Price, John, additional, Mansoor, Wasat, additional, and Oberg, Kjell E., additional

Published
2013
Full Text
View/download PDF

285. Cushing's syndrome

Author

Daniel, Eleni and Newell-Price, John

Abstract

Endogenous Cushing's syndrome results from prolonged, excessive, inappropriate concentrations of circulating cortisol. Cushing's syndrome should be considered in patients with unusual features for age, patients with multiple and progressive features, children with decreasing height percentile and increasing weight, and patients with adrenal adenoma found incidentally. Endogenous Cushing's syndrome is more common in women than men. Adrenocorticotrophic hormone (ACTH)-dependent causes account for about 80% of cases. Of ACTH-dependent cases, 80% result from pituitary adenomas (Cushing's disease) and the remainder from ectopic ACTH secretion. Non-ACTH-dependent Cushing's syndrome is caused by benign adrenal adenomas in 60% and carcinomas in 40%. Specialist assessment and treatment warrants referral to major centres. For diagnosis, the most discriminating clinical features are thin skin, easy bruising and proximal myopathy. Biochemical diagnosis is by a combination of low-dose dexamethasone suppression tests, assessment of loss of circadian rhythm and urinary free cortisol. When differentiating pituitary and non-pituitary sources of ACTH, reliance should be placed on biochemical evaluation. Medical therapy is often used preoperatively to lower plasma cortisol, postoperatively to control concentrations in patients not cured, and after radiotherapy. Trans-sphenoidal surgery is the treatment of choice for Cushing's disease; laparoscopic bilateral adrenalectomy can be used in refractory cases.

Published
2017
Full Text
View/download PDF

299. Home Waking Salivary Cortisone to Screen for Adrenal Insufficiency.

Author

Debono, Miguel, Elder, Charlotte J., Lewis, Jen, Fearnside, Jane, Caunt, Sharon, Dixon, Simon, Jacques, Richard M., Newell-Price, John, Whitaker, Martin J., Keevil, Brian, and Ross, Richard J.

Subjects
SALIVA analysis, CONFIDENCE intervals, PHLEBOTOMY, LIQUID chromatography, ADRENAL insufficiency, MEDICAL screening, MASS spectrometry, DISEASE prevalence, RESEARCH funding, RECEIVER operating characteristic curves, SENSITIVITY & specificity (Statistics), COLLECTION & preservation of biological specimens, ADRENOCORTICOTROPIC hormone, HYDROCORTISONE, LONGITUDINAL method
Abstract

Background: Worldwide, adults and children are at risk of adrenal insufficiency as a result of adrenal suppression from use of anti-inflammatory glucocorticoids and opiates, as well as infectious diseases. The adrenocorticotropin (ACTH) stimulation test is the reference standard for diagnosis of adrenal insufficiency but requires clinic attendance and venesection. Salivary cortisone reflects free serum cortisol, and samples can be collected at home and posted to a laboratory. We tested whether home waking salivary cortisone level could be used to screen for adrenal insufficiency. Methods: A prospective, diagnostic accuracy study was performed in patients at high risk of adrenal insufficiency. Patients collected a home salivary sample on waking and then attended the clinical facility for an ACTH stimulation test. Salivary cortisone was measured by liquid chromatography-tandem mass spectrometry. Receiver-operating characteristic curves were computed, and positive and negative predictive values were calculated. Results: Two hundred twenty patients were recruited. As measured by an ACTH stimulation test, the prevalence of adrenal insufficiency was 44%. The area under the receiver-operating characteristic curve for waking salivary cortisone as a predictor of adrenal insufficiency was 0.95 (95% confidence interval [CI], 0.92 to 0.97). Cutoffs to ensure a minimum of 95% sensitivity and specificity gave a negative predictive value of 96% (95% CI, 90 to 99) and a positive predictive value of 95% (95% CI, 87 to 99) to exclude and confirm adrenal insufficiency, respectively. Waking salivary cortisone data provided information similar to that of an ACTH stimulation test in 70% of participants. Eighty-three percent of patients preferred home salivary collection to clinic attendance. Conclusions: Home waking salivary cortisone sampling has accuracy for the diagnosis of adrenal insufficiency similar to that of a standard ACTH stimulation test. Patients found the at-home test to be more convenient than the hospital-based test. (Funded by the National Institute for Health Research.) [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results